Novo Nordisk CEO Steps Down Amid $300 Billion Stock Drop and Escalating Weight-Loss Drug Battle

Novo Nordisk announced that CEO Lars Fruergaard Jørgensen will step down in response to growing market pressures and a sharp decline in the company’s share price. The decision was made jointly by Jørgensen, the company board, and the Novo Nordisk Foundation. The announcement cited recent market challenges, the falling stock value, and the foundation’s wishes…